This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shelburne, S. A.
Right arrow Articles by Hamill, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shelburne, S. A.
Right arrow Articles by Hamill, R. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 4016-4019, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4016-4019.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Killing of Community-Associated Methicillin-Resistant Staphylococcus aureus with Drug Combinations

Samuel A. Shelburne,1 Daniel M. Musher,1,2 Kristina Hulten,3 Heather Ceasar,2 Michael Y. Lu,2 Imran Bhaila,2 and Richard J. Hamill1,2*

Section of Infectious Diseases, Veterans Affairs Medical Center,1 Section of Infectious Diseases, Department of Medicine,2 Section of Infectious Diseases, Department of Pediatrics,3 Baylor College of Medicine, Houston, Texas 770304

Received 13 February 2004/ Returned for modification 24 May 2004/ Accepted 30 June 2004

This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

* Corresponding author. Mailing address: Section of Infectious Diseases (111G), Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd., Houston, TX 77030-4211. Phone: (713) 794-7384. Fax: (713) 794-7045. E-mail: richard.hamill{at}med.va.gov.

Antimicrobial Agents and Chemotherapy, October 2004, p. 4016-4019, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4016-4019.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nguyen, H. M., Graber, C. J. (2009). Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother 0: dkp377v1-dkp377 [Abstract] [Full Text]  
  • Rose, W. E., Poppens, P. T. (2009). Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 63: 485-488 [Abstract] [Full Text]  
  • Ikonomidis, A., Michail, G., Vasdeki, A., Labrou, M., Karavasilis, V., Stathopoulos, C., Maniatis, A. N., Pournaras, S. (2008). In Vitro and In Vivo Evaluations of Oxacillin Efficiency against mecA-Positive Oxacillin-Susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 3905-3908 [Abstract] [Full Text]  
  • Riedel, D. J., Weekes, E., Forrest, G. N. (2008). Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2463-2467 [Abstract] [Full Text]  
  • Perlroth, J., Kuo, M., Tan, J., Bayer, A. S., Miller, L. G. (2008). Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature. Arch Intern Med 168: 805-819 [Abstract] [Full Text]  
  • Chi, C.-Y., Lauderdale, T.-L., Wang, S.-M., Wu, J.-M., Yang, Y.-J., Liu, C.-C. (2008). Health Care-Associated Endocarditis Caused by Staphylococcus aureus with Reduced Susceptibility to Vancomycin. J. Clin. Microbiol. 46: 810-813 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Kaka, A. S., Rueda, A. M., Shelburne, S. A. III, Hulten, K., Hamill, R. J., Musher, D. M. (2006). Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 680-683 [Abstract] [Full Text]  
  • Kollef, M. H., Micek, S. T. (2005). Staphylococcus Aureus Pneumonia: A "Superbug" Infection in Community and Hospital Settings. Chest 128: 1093-1097 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»